Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
4 hedge funds and large institutions have $1.87K invested in Protagenic Therapeutics Warrant in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 2 → 4 (+2)
0.48% more ownership
Funds ownership: 4.68% → 5.16% (+0.48%)
72% less capital invested
Capital invested by funds: $6.76K → $1.87K (-$4.88K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$537 |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
New York
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $1.45K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $218 | +$537 | +26,600 | New |
|
|
GS
3
GTS Securities
New York
| $202 | -$2 | -100 | -0.4% |
|
|
4
Bank of America
Charlotte,
North Carolina
| $1 | +$2 | +100 | New |
|
PTIXW Hedge Fund Activity: Q2 2024 in Review
4 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q2 2024, worth a combined $1.87K — down 72% from $6.76K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PTIXW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $537. The largest seller was GTS Securities, cutting an estimated $2.
- 4 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q2 2024, up from 2 in Q1 2024.
- Funds reported $1.87K of Protagenic Therapeutics Warrant stock for Q2 2024, down 72% quarter-over-quarter.
- 2 funds opened new Protagenic Therapeutics Warrant positions in Q2 2024 and 0 closed out, a net change of +2 holders.
- The largest Protagenic Therapeutics Warrant buyer in Q2 2024 was Susquehanna International Group, an estimated $537 added.
- The largest Protagenic Therapeutics Warrant seller in Q2 2024 was GTS Securities, an estimated $2 sold.
Based on aggregated 13F filings for Q2 2024.